Status:
COMPLETED
Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs
Lead Sponsor:
Northwestern Ophthalmic Institute S.C.
Collaborating Sponsors:
Research to Prevent Blindness
Conditions:
Primary Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
41+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, lata...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma or ocular hypertension.
- Must be over 40 years of age.
- Intraocular pressure must be 18 mm Hg or higher after 6 weeks of treatment (run-in) with a prostaglandin analog (bimatoprost, latanoprost, or travoprost).
Exclusion
- History of angle closure or narrow angle.
- Previous intraocular surgery.
- Laser trabeculoplasty within 3 months prior to screening.
- History of uveitis or intraocular inflammation.
- Use of medications other than the study medications that are known to affect IOP (e.g., beta-blockers, steroids, or angiotensin II blockers) within 3 months of study entry or during the study.
- Intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides, alpha-agonists, or the preservative benzalkonium chloride.
- Women of childbearing age who are pregnant or not using contraception.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00675207
Start Date
January 1 2006
End Date
July 1 2007
Last Update
May 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Ophthalmic Institute S.C.
Glenview, Illinois, United States, 60026